Attached files
| file | filename |
|---|---|
| EX-2.2 - EX-2.2 - AYTU BIOPHARMA, INC | d912919dex22.htm |
| EX-3.1 - EX-3.1 - AYTU BIOPHARMA, INC | d912919dex31.htm |
| EX-10.3 - EX-10.3 - AYTU BIOPHARMA, INC | d912919dex103.htm |
| EX-10.2 - EX-10.2 - AYTU BIOPHARMA, INC | d912919dex102.htm |
| EX-10.8 - EX-10.8 - AYTU BIOPHARMA, INC | d912919dex108.htm |
| EX-99.1 - EX-99.1 - AYTU BIOPHARMA, INC | d912919dex991.htm |
| EX-99.2 - EX-99.2 - AYTU BIOPHARMA, INC | d912919dex992.htm |
| EX-10.1 - EX-10.1 - AYTU BIOPHARMA, INC | d912919dex101.htm |
| EX-10.11 - EX-10.11 - AYTU BIOPHARMA, INC | d912919dex1011.htm |
| EX-10.12 - EX-10.12 - AYTU BIOPHARMA, INC | d912919dex1012.htm |
| 8-K - 8-K - AYTU BIOPHARMA, INC | d912919d8k.htm |
| EX-99.3 - EX-99.3 - AYTU BIOPHARMA, INC | d912919dex993.htm |
| EX-2.1 - EX-2.1 - AYTU BIOPHARMA, INC | d912919dex21.htm |
| EX-10.7 - EX-10.7 - AYTU BIOPHARMA, INC | d912919dex107.htm |
Exhibit 16.1
April 22, 2015
Securities and Exchange Commission
450 Fifth Street N.W.
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements of Rosewind Corporation pertaining to our firm included in Item 4.01 of the Form 8-K dated April 22, 2015 and are in agreement with the statements contained in that document pertaining to our firm.
Sincerely,
/s/ HJ & Associates, LLC
HJ & Associates, LLC
